ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2022
Survey of pharmacists on their roles and perceptions of outpatient parenteral antimicrobial therapy in the United States.
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- High Rate of Adverse Events in Patients Receiving Oral Antimicrobials Under a COpAT Monitoring Protocol.Open forum infectious diseases · 2026Article
- Outpatient Parenteral Antimicrobial Therapy Practice Variability Across Veterans Affairs Hospitals.JAMA network open · 2026Article
- 2026 Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.JAC-antimicrobial resistance · 2026Review
- Propensity Score-Weighted Analysis of the Impact of Outpatient Parenteral Antimicrobial Therapy Plan Reconciliation on Unscheduled Care.Open forum infectious diseases · 2025Article
- Current practices in outpatient parenteral antimicrobial therapy programmes: an international multi-centre survey.JAC-antimicrobial resistance · 2025Article
- A data-driven financial justification for an outpatient infectious diseases pharmacist.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Antimicrobial Stewardship Practices in Outpatient Parenteral Antimicrobial Therapy Programs in the United States.Open forum infectious diseases · 2024Article
- Outpatient Parenteral Antimicrobial Therapy in a Safety Net Hospital: Opportunities for Improvement.Open forum infectious diseases · 2024Article
- Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians.Open forum infectious diseases · 2024Review
- The OPAT opportunity for beta-lactam individualization.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- A Bundle of the Top 10 OPAT Publications in 2022.Open forum infectious diseases · 2023Review
- Treatment decisions in VRE bacteraemia: a survey of infectious diseases pharmacists.JAC-antimicrobial resistance · 2023Article
- Current Practices and Opportunities for Outpatient Parenteral Antimicrobial Therapy in Hospitals: A National Cross-Sectional Survey.Antibiotics (Basel, Switzerland) · 2022Article
- Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.Antibiotics (Basel, Switzerland) · 2022Review
- From sea to shining IV: the current state of OPAT in the United States.Therapeutic advances in infectious diseaseReview
- Taking the route less traveled: on the way to COpAT.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To define outpatient parenteral antimicrobial therapy (OPAT) clinical pharmacy practice across the United States, specifically pharmacist functions, design of pharmacist involvement, and to compare pharmacist training of those who practice in OPAT to infectious diseases pharmacists who do not. Methods: A survey of a possible 32 questions was emailed to the American College of Clinical Pharmacists (ACCP) Infectious Diseases Practice and Research Network (PRN) e-mail list. Results were focused on US-based respondents. Participants: In total, 87 pharmacists responded; 27 of these pharmacists (31%) practiced in OPAT. Results: Training background did not differ between groups. Programs with an OPAT pharmacist were more likely to have a formal OPAT team compared to those without an OPAT pharmacist ( Conclusion: Pharmacist nondispensing involvement in OPAT is an emerging trend in the United States with wide variability in program structure and pharmacist tasks. A ratio of 1 OPAT pharmacist for every 45-70 OPAT patients is proposed to facilitate expansion of pharmacist clinical practice in OPAT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.